Production (Stage)
Inozyme Pharma, Inc.
INZY
$3.98
-$0.01-0.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 84.78M | 113.09M | 131.61M | 144.52M | 166.15M |
| Total Receivables | -- | 467.00K | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 8.55M | 6.81M | 9.33M | 8.44M | 8.17M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 311.00K | 311.00K | -- | -- | -- |
| Total Current Assets | 93.64M | 120.68M | 140.94M | 152.96M | 174.32M |
|
|
|||||
| Total Current Assets | 93.64M | 120.68M | 140.94M | 152.96M | 174.32M |
| Net Property, Plant & Equipment | 1.02M | 1.35M | 1.66M | 1.98M | 2.31M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 509.00K | 1.16M | 769.00K | 769.00K | 311.00K |
| Total Assets | 95.16M | 123.18M | 143.36M | 155.71M | 176.94M |
|
|
|||||
| Total Accounts Payable | 3.67M | 2.53M | 2.21M | 3.53M | 2.17M |
| Total Accrued Expenses | 12.74M | 15.95M | 11.57M | 11.06M | 9.31M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 26.37M | 15.42M | 4.56M | 959.00K | 934.00K |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 42.78M | 33.90M | 18.34M | 15.54M | 12.41M |
|
|
|||||
| Total Current Liabilities | 42.78M | 33.90M | 18.34M | 15.54M | 12.41M |
| Long-Term Debt | 20.59M | 31.46M | 42.07M | 45.33M | 45.03M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | 164.00K | 419.00K | 669.00K |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 63.37M | 65.36M | 60.57M | 61.29M | 58.11M |
|
|
|||||
| Common Stock & APIC | 447.80M | 445.71M | 443.48M | 430.83M | 428.22M |
| Retained Earnings | -415.99M | -387.95M | -360.88M | -336.31M | -309.28M |
| Treasury Stock & Other | -5.00K | 69.00K | 186.00K | -103.00K | -105.00K |
| Total Common Equity | 31.80M | 57.83M | 82.79M | 94.42M | 118.84M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 31.80M | 57.83M | 82.79M | 94.42M | 118.84M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 31.80M | 57.83M | 82.79M | 94.42M | 118.84M |
|
|
|||||